Hipertermik İntraperitoneal Kemoterapi Uygulaması: Çalışan Güvenliği

Year 2023, Volume: 7 Issue: 1, 237 - 247, 31.01.2023

Nurcan Boyacıoğlu , Sultan Özkan

https://doi.org/10.46237/amusbfd.1071637

Abstract

Peritoneal yüzey malignitelerin de yeni tedavi yaklaşımı sitoredüktif cerrahi ile birlikte kombine hipertermik intraperitoneal kemoterapi uygulamasıdır. Sitoredüksiyon cerrahi ile tüm makroskopik tümörlerin çıkarılması, Hipertermik İntraperitoneal Kemoterapi (HİPEK) ile de mikroskobik tümör hücrelerinin yok edilmesi amaçlanmaktadır. Bu yöntem, plazma-periton bariyerini kullanarak kemoterapötik ajanların ısı ile birlikte daha yüksek konsantrasyonlarda ve daha az sitotoksik yan etki ile uygulanmasına olanak sağlamaktadır. Ancak işlem esnasında ameliyathane çalışanlarının kemoterapötik ajanlar ile maruziyet riski söz konusudur. Bu derlemede HİPEK işlemi esnasında maruziyet yolları ve çalışanların sağlığını korumaya yönelik güvenlik önlemleri konusunda literatür bilgileri ele alınmıştır.

Keywords

Ameliyathane, Çalışan güvenliği, Kemoterapi, HİPEK, Hemşire

Supporting Institution

yok

Project Number

yok

Thanks

yok

Hyperthermic Intraperitoneal Chemotherapy Application: Employee Safety

Abstract

A new treatment approach for peritoneal surface malignancies is cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. It is aimed to remove all macroscopic tumors with cytoreduction surgery, and to destroy microscopic tumor cells with Hyperthermic Intraperitoneal Chemotherapy (HIPEC). This method, using the plasma-peritoneal barrier, allows the administration of chemotherapeutic agent at higher concentrations with temperature and with less cytotoxic side effects. However, there is a risk of exposure of operating room workers to chemotherapeutic agent during the procedure. In this review, literature information on exposure routes and safety measures to protect the health of workers during the HIPEC procedure is discussed.

Keywords

Operating room, Employee safety, Chemotherapy, HIPEC, nursing

Project Number

yok

References

• 1. Sağlık Teknolojisi Değerlendirme Projesi. Hipertermik İntraperitoneal Kemoterapi. Ekim, 2017.
• 2. Esquivel, J., Sticca,R., Sugarbaker, P., Levine, E., Yan, T. D., Alexander, R., et al. (2007). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Annals of Surgical Oncology. 14(1),128–133.
• 3. Jacquet, P., & Sugarbaker, PH. (1996). Peritoneal-plasma barrier.Sugarbaker PH. Peritoneal carcinomatosis: principles of management (ss.53-63). Boston: Kluwer Academic Publishers.
• 4. Dunn, D. (2019). Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.AORNJournal. 110(5), 479–499.
• 5. González-Bayón, L., González-Moreno, S., & Ortega-Pérez, G. (2006). Safety considerations for operating room personnel during hyperthermic intraoperative intraperitoneal chemotherapy perfusion. European Journal of Surgical Oncology.32(6),619–624.
• 6. National Institute for Occupational Safety and Health. NIOSH List of Hazardous Drugs in Healthcare Settings, 2020.
• 7. Kyriazanos, I., Kalles, V., Stefanopoulos, A., Spiliotis, J., & Mohamed, F. (2016). Operating personnel safety during the administration of hyperthermic intraperitoneal chemotherapy (HIPEC). Surgical Oncology. 25(3), 308–314.
• 8. González-Moreno, S., González-Bayón, L., & Ortega-Pérez, G. (2012). Hyperthermic intraperitoneal chemotherapy. methodology and safety considerations. Surgical Oncology Clinics of North America. 21(4), 543–557.
• 9. Riboli, G.B., Catalina, R., & Caregnato, A. (2022).Occupational safety measures in the intraoperative period of hyperthermic intraperitoneal chemotherapy : scoping review. Acta Paul Enferm. 35,1–8.
• 10. Andréasson, S.N., Anundi, H., Sahlberg, B., Ericsson, C.G., Wålinder, R., Enlund, G., et al. (2009). Peritonectomy with high voltage electrocautery generates higher levels of ultrafine smoke particles. European Journal of Surgical Oncology. 35(7), 780–784.
• 11. Karadağ, E.S., Vural, Ç., Yıldırım, G.Ç., Can, Ö.S., Alanoğlu, Z., & Alkış, N. (2020). Anesthesia management and perioperative outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of Ankara University Faculty Medicine. 73(3), 276–282.
• 12. Fencl, J.L. (2017). Guideline implementation: surgical smoke safety. AORN Journal. 105(5), 488–497.
• 13. Topgül, K., Malazgirt, Z., & Bişgin, T. (2017). Safety of health workers during hyperthermic ıntraperitoneal chemotherapy procedure. Turkish Journal of Colorectal Disease. 27, 110–116.
• 14. Bhatt, A., Mittal, S., & Gopinath, K.S. (2016). Safety considerations for health care workers involved in cytoreductive surgery and perioperative chemotherapy. Indian Journal of Surgical Oncology. 7(2), 249–257.
• 15. Stuart, O.A., Stephens, A.D., Welch, L., & Sugarbaker, P.H. (2002). Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. Annals of Surgical Oncology. 9(2), 186–191.
• 16. Rodier, S., Saint-Lorant, G., Guilloit, J.M., Palix, A., Divanon, F., Sichel, F., et al. (2017). Is hyperthermic intraperitoneal chemotherapy (HIPEC) safe for healthcare workers?. Surgical Oncology. 26(3), 242–251.
• 17. Villa, A.F., El Balkhi, S., Aboura, R., Sageot, H., Hasni-Pichard, H., Pocard, M., et al. (2015). Evaluation of oxaliplatin exposure of healthcare workers during heated intraperitoneal perioperative chemotherapy (HIPEC). Indian Health. 53(1), 28–37.
• 18. Saint-Lorant, G., Rodier, S., Guilloit, J.M., Ndaw, S., Melczer, M., Lagadu, S., et al. (2021). Is the blood of a surgeon performing HIPEC contaminated by irinotecan, its major metabolites and platinum compounds?. Pleura and Peritoneum. 6(2), 49–55.
• 19. Ndaw, S., Hanser, O., Kenepekian, V., Vidal, M., Melczer, M., Remy, A., et al. (2018). Occupational exposure to platinum drugs during intraperitoneal chemotherapy. Biomonitoring and surface contamination. Toxicology Letters 298(May), 171–176.
• 20. Schmid, K., Boettcher, M.I., Pelz, J.O.W., Meyer, T., Korinth, G., Angerer, J., et al. (2006). Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with mitomycin C. European Journal of Surgical Oncology. 32(10), 1222–1225.
• 21. Caneparo, A., Massucco, P., Vaira, M., Maina, G., Giovale, E., Coggiola, M., et al. (2014). Contamination risk for operators performing semi-closed HIPEC procedure using cisplatin. European Journal of Surgical Oncology. 40(8), 925–929.
• 22. Guerbet, M., Goullé, J.P., & Lubrano, J. (2007). Evaluation of the risk of contamination of surgical personnel by vaporization of oxaliplatin during the intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC). European Journal of Surgical Oncology. 33(5), 623–626.
• 23. Zhengzheng Xie, M.S., Li, Y., Yan, D., Hu, X., Liu Liu M.S., Lulu Sun, B.S., et al. (2021). Evaluation of exposure risk for healthcare personnel performing the open technique HIPEC procedure using cisplatin. Gynecologic Oncology. 161(1), 261–263.
• 24. Schierl, R., Novotna, J., Piso, P., Böhlandt, A., & Nowak, D. (2012). Low surface contamination by cis/oxaliplatin during hyperthermic intraperitoneal chemotherapy (HIPEC). European Journal of Surgical Oncology. 38(1), 88–94.
• 25. Schenk, K.E., Schierl, R., Angele, M., Burkhart-Reichl, A., Glockzin, G., Novotny, A., et al. (2016). Cisplatin and oxaliplatin surface contamination in intensive care units (ICUs) and hospital wards during attendance of HIPEC patients. International Archives of Occupational and Environmental Health. 89(6), 991–996.
• 26. Kushnir, C.L., Fleury, A.C., Couch, J., Hill, M.C., & Spirtos, N.M. (2013). Evaluation of exposures to healthcare personnel from cisplatin during a mock demonstration of intra-operative intraperitoneal chemotherapy administration. Gynecologic Oncology. 130(2), 350–353.
• 27. González-Moreno, S., Ortega-Pérez, G., Alonso-Casado, O., Galipienzo-García, J., Linero-Noguera, M.J., & Salvatierra-Díaz, D. (2018). Techniques and safety ıssues for ıntraperitoneal chemotherapy. Surgical Oncology Clinics of North America. . 2018; 27(3), 495–506.
• 28. Wallemacq, P.E., Capron, A., Vanbinst, R., Boeckmans, E., Gillard, J., & Favier, B. (2006). Permeability of 13 different gloves to 13 cytotoxic agents under controlled dynamic conditions. American Journal of Health- System Pharmacy. 63(6), 547–556.
• 29. Raspé, C.Flöther, L., Schneider, R., Bucher, M., & Piso, P. (2017). Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. European Journal of Surgical Oncology. 43(6), 1013– 1027.